(NASDAQ: AVLN) Avalyn Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.51%.
Avalyn Pharma's earnings in 2026 is N/A.On average, 5 Wall Street analysts forecast AVLN's earnings for 2026 to be -$140,482,711, with the lowest AVLN earnings forecast at -$165,530,910, and the highest AVLN earnings forecast at -$125,218,827. On average, 5 Wall Street analysts forecast AVLN's earnings for 2027 to be -$116,365,508, with the lowest AVLN earnings forecast at -$132,946,085, and the highest AVLN earnings forecast at -$96,823,479.
In 2028, AVLN is forecast to generate -$109,884,009 in earnings, with the lowest earnings forecast at -$119,043,227 and the highest earnings forecast at -$98,685,469.